Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vincent Medical Holdings's annualized ROCE % for the quarter that ended in Dec. 2025 was 16.96%.
Vincent Medical Holdings (HKSE:01612) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vincent Medical Holdings (HKSE:01612) has a ROCE % of 16.96% as of Dec. 2025.
Is Vincent Medical Holdings' ROCE % too high?
Vincent Medical Holdings' current ROCE % is 16.96%. The Medical Devices & Instruments industry median ROCE % is 2.18. Vincent Medical Holdings' value of 16.96% is 678% above this industry median. Overall, Vincent Medical Holdings has a GF Score™ of 49/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vincent Medical Holdings' ROCE % compare to ABT and SYK?
Vincent Medical Holdings' ROCE % of 16.96% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.18. Vincent Medical Holdings' value of 16.96% is 678% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.18, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vincent Medical Holdings's current ROCE % of 16.96% is 678% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vincent Medical Holdings's current ROCE % is 16.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vincent Medical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Vincent Medical Holdings (HKSE:01612) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.58, compared to a current price of HK$0.71 — trading 22.4% above its estimated fair value. The current ROCE % is 16.96% and 678% above the Medical Devices & Instruments industry median of 2.18. Vincent Medical Holdings' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vincent Medical Holdings (HKSE:01612), the current ROCE % is 16.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vincent Medical Holdings (HKSE:01612) Overvalued in 2026?
Based on GuruFocus' analysis, Vincent Medical Holdings stock appears to be overvalued.
The current stock price of HK$0.71 is trading 22.4% above its estimated GF Value™ of HK$0.58.
GuruFocus considers Vincent Medical Holdings to be Modestly Overvalued.
Key valuation signals for HKSE:01612:
ROCE %: 16.96%
GF Value™: HK$0.58 vs. price of HK$0.71 (22.4% above fair value)
Industry Position: 678% above the Medical Devices & Instruments median
No single metric tells the full story. See the HKSE:01612 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vincent Medical Holdings Ltd is an investment holding company engaged in the manufacturing and selling of medical devices focusing on imaging disposable products on an OEM basis to one of the world's diagnostic imaging solutions providers. The company operates in two segments: OEM (original equipment manufacturing) and OBM (original brand manufacturing). The OEM segment manufactures products as per the customer's requirements. The OBM segment includes research, development, manufacturing, marketing, and sales of medical devices under the Inspired Medical, and Hand of Hope brands. The geographical segments of the company includes the United States, Spain, the PRC, Japan, Costa Rica, the Netherlands, Germany, and Others. It derives its maximum revenue from Spain.
49GF Score
Get the complete analysis for HKSE:01612
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01612 has been successfully added to your 
